Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)

Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12–13

HOS-134488 · Präparat HOS-097580

12 INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS Medicinal products by Interaction Geometric mean change Recommendations concerning co- therapeutic areas (%) administration Alfuzosin Based on theoretical considerations Co-administration of darunavir with darunavir is expected to increase low dose ritonavir and alfuzosin is alfuzosin plasma concentrations. contraindicated (see section 4.3). (CYP3A inhibition) ANAESTHETIC Alfentanil Not studied. The metabolism of The concomitant use with darunavir alfentanil is mediated via CYP3A, and and low dose ritonavir may require may as such be inhibited by darunavir to lower the dose of alfentanil and co-administered with low dose requires monitoring for risks of ritonavir. prolonged or delayed respiratory depression. ANTIANGINA/ANTIARRHYTHMIC Disopyramide Not studied. Darunavir is expected to Caution is warranted and Flecainide increase these antiarrhythmic plasma therapeutic concentration Lidocaine concentrations. monitoring, if available, is (systemic) (CYP3A and/or CYP2D6 inhibition) recommended for these Mexiletine antiarrhythmics when co- Propafenone administered with darunavir with low dose ritonavir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) alfuzosin (HOS-086139) propafenone (HOS-084530) flecainide (HOS-086203) lidocaine (HOS-108866) mexiletine (HOS-086341) disopyramide (HOS-085595) ritonavir (HOS-084521)